On this page, you will find different kinds of study results:
• A Lay summary which is a summary of clinical trial results written in an easy-to-understand way.
• A summary of results called synopsis which is written in scientific language. It is prepared for Medicines Agencies and Ethics Committees,
• A scientific publication which presents results for scientists and medical doctors.
|Protocol Code||Study Title||Active substance/Medical device||Study Phase||Therapeutic Area|
|CL1-68587-003||A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Malignancies Who Have…||
|CL1-68587-002||Phase I, open label, dose-escalation study to evaluate the safety, expansion, persistence and biological activity…||
|CL1-64315-001||Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic…||S064315||Phase 1||Cancers|
|CL1-55746-001||Phase I dose-escalation study of oral administration of the selective Bcl2 inhibitor S55746 in patients…||S055746||Phase 1||Cancers|
|CL1-49076-003||Phase I/II study of oral administration of S 49076 given in combination with gefitinib in…||S049076||Phase 1-2||Cancers|
|CL1-49076-001||Phase I dose-escalation study of oral administration of MET Tyrosine Kinase Inhibitor S 49076 in…||S049076||Phase 1||Cancers|
|CL1-20098-081||Evaluation of the effect of agomelatine and escitalopram on emotions and motivation in healthy male…||
|Phase 1||Neuropsychiatric Diseases|
|CL1-078454-018||Long-term safety study of abexinostat (S 078454) per os given as single-agent in haematological malignancies…||
|CL1-055746-002||Phase I dose-escalation study of the orally administrered selective Bcl-2 inhibitor S055746 as monotherapy for…||S055746||Phase 1||Cancers|